Illumina introduceert VeriSeq™ Analysis Software (48 stalen), geoptimaliseerde data-analyse voor niet-invasieve prenatale tests
SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NASDAQ: ILMN) heeft vandaag bekendgemaakt dat het aan de richtlijn IVD voldoet en een CE-markering heeft gekregen voor een uitgebreide versie van VeriSeq™ NIPT Analysis Software, voor klinische laboratoria in de Europese Unie. De geüpdatete versie van VeriSeq™ NIPT Analysis Software werkt met een innovatieve methode voor de verwerking van stalen en is ontwikkeld voor grotere partijen van 48 stalen, versus de huidige hoeveelheid van 16 stalen. Zodoende is opschalen mogelijk, om in de toekomst te voldoen aan de vraag op de groeimarkt van niet-invasieve, prenatale tests. Dankzij dit nieuwe product beschikken klinische laboratoria in de Europese Unie over snelle en betrouwbare software voor de analyse van sequencing voor NIPT.
De CE-markering houdt in dat de analysesoftware voldoet aan de kwaliteitseisen die de Europese richtlijn voor diagnostiek in vitro (98/79/EC) stelt. De markering verzekert dat de software is gemaakt om de strikte veiligheids- en gezondheidscriteria van de EU te halen. De nieuwe software introduceert een methode met aan elkaar gekoppelde uiteindes van een sequentie.
Illumina Debuts VeriSeq™ Analysis Software (48 Samples), Optimized Data Analysis for Noninvasive Prenatal Testing |
|||||
|
SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NASDAQ: ILMN) today announced that it has declared conformity with the requirements of the IVD Directive and has applied the CE mark to an expanded VeriSeq™ NIPT Analysis Software for clinical laboratories in the European Union (EU). This updated VeriSeq™ NIPT Analysis Software includes an innovative method for processing samples and is designed for larger batches of 48 samples, versus the current 16 samples, which can scale to meet the future demands of the growing noninvasive prenatal testing (NIPT) market. Using this software, clinical labs in the EU have access to fast and reliable software for analysis of sequencing data for NIPT. The CE marking signifies that the analysis software complies with the quality standards set by the European In Vitro Diagnostics Directive (98/79/EC), and certifies that it has been created and manufactured to meet strict safety and health criteria for distribution in the EU. This new software introduces a method that utilizes paired-end sequencing data. “The update to the VeriSeq™ NIPT Analysis Software is another important milestone towards providing a more complete high-quality NIPT solution to our laboratory partners in the EU,” said Jeff Hawkins, Vice President and General Manager of Reproductive and Genetic Health at Illumina. “With this software, Illumina is enabling more clinical laboratories to implement NIPT testing efficiently and affordably in-house, increasing overall workflow efficiency and reducing the costs of testing.” The VeriSeq™ NIPT Analysis Software generates quantitative scores to aid in the detection and differentiation of fetal aneuploidy status for chromosomes 21, 18, 13, X and Y by analyzing sequencing data generated from cell-free DNA fragments isolated from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation. The release of the VeriSeq™ NIPT Analysis Software (48 Samples) represents an important step toward Illumina’s plan to provide a full CE-IVD NIPT solution. The upcoming VeriSeq™ NIPT Solution will include CE-IVD marked assay specific reagents with a supporting clinical accuracy study. About Illumina, Inc. Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina. Forward-Looking Statements This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for new products and services and FDA submission dates and intentions for certain products and services. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services, and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release. View source version on businesswire.com: http://www.businesswire.com/news/home/20170130005259/en/ Contacts Illumina, Inc. |
|||||